Paul Curmi

Paul Curmi is managing director and head of investor relations, business and product management. He became part of First Eagle in 2022 upon the firm’s acquisition of Napier Park Global Capital, which he had joined in Napier Park’s global product and investor relations effort. Napier Park separated from Citigroup’s alternative investment arm, Citi Capital Advisors, in 2013. Paul is also the chairman of Napier Park’s ESG committee. Paul earned a BS in business administration from Fordham University. He is on the board of directors of Advancing CTNNB1 Cures and Treatments, a non-profit which supports the development of treatments and cures for CTNNB1 Syndrome.